The modified lysozyme molecule showed a remarkable in vitro antiviral activity in a herpes simplex virus model, both in terms of preventing cell infection and, most importantly, and inhibiting virus replication when the drug was added to cells previously infected with the virus (the IC50 decreased from 170 mg/mL to 6 mg/mL). The gene discussed is LYZ; the disease is infection.